Rosuvastatin

• Changes in plaque characteristics after short-term statin therapy assessed with coronary CT (INTENSE) Pending
  2025-522868-32-00 Phase II/III 1 country Semmelweis University
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 Phase III 5 countries Novartis Pharma AG
• EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI) Recruiting
  2025-521452-30-01 Phase III 1 country Region Midtjylland
• Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head… Recruiting
  2024-514523-42-00 Phase III 1 country Medical University Of Lodz
• StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting
  2024-517343-31-00 Phase IV 1 country Amsterdam UMC Stichting
• The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and relate… Recruiting
  2024-516967-10-00 Phase IV 1 country Medical University Of Vienna
• An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced… Recruiting
  2023-503865-48-00 Phase II 4 countries Taiho Oncology Inc.
• The Pragmatic EE-PRS Trial assessing Polygenic Risk Driven Statin Therapy for Cardiovascular Disease Prevention Ended
  2024-513424-42-01 Phase IV 1 country University Of Tartu
• A clinical trial to evaluate efficacy, safety and cost-efficacy of gene analysis strategy in a population at risk of cardiovascular disease … Ended
  2023-509418-12-00 Phase IV 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P… Ended
  2024-511126-31-00 Phase III 6 countries Novartis Pharma AG
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III 24 countries Novartis Pharma AG
• Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia –… Ended
  2023-504914-31-00 Phase III/IV 5 countries KRKA tovarna zdravil d.d. Novo mesto
• A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended
  2024-511076-32-00 Phase IV 1 country Novartis Pharma GmbH
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 Phase IV 8 countries Novartis Pharma AG

Showing 1–14 of 14 trials